Results 191 to 200 of about 12,954,964 (236)
Some of the next articles are maybe not open access.
5-Alpha reductase inhibitors in active surveillance
Current Opinion in Urology, 2014Active surveillance is now one of the recommended treatment options for low-risk prostate cancer (PCa). However, about 10-30% of men on active surveillance will progress and require definitive therapy. In this review, we examine the role of 5-alpha reductase inhibitors (5-ARIs) in secondary prevention among men with low-risk PCa who opted to be managed
Patrick O, Richard, Antonio, Finelli
openaire +2 more sources
5-Alpha-reductase inhibitors in diseases of the prostate
Current Opinion in Endocrinology, Diabetes & Obesity, 2014To summarize the history of the use of 5-alpha-reductase inhibitors in the treatment of urologic diseases and discuss the current practices and indications for therapy.5-Alpha-reductase inhibitors (5-ARIs) are indicated in the treatment of benign prostatic hyperplasia (BPH) with obstructive urinary symptoms to reduce symptoms, reduce the risk of acute ...
Robert J, Carrasquillo +2 more
openaire +2 more sources
Finasteride: A slow-binding 5.alpha.-reductase inhibitor
Biochemistry, 1993A microsomal preparation of human prostatic tissue was used to study the kinetics of interaction of steroid 5 alpha-reductase with finasteride, a known 5 alpha-reductase inhibitor. This molecule has been reported to reversibly bind 5 alpha-reductase in a competitive manner to testosterone with a Ki value in the 10 nM range.
B, Faller, D, Farley, H, Nick
openaire +2 more sources
The role of 5-alpha-reductase inhibitors in active surveillance
Current Opinion in Urology, 2012Active surveillance is now considered one of the preferred treatments for men with favorable risk prostate cancer (PCa). Unfortunately, 30-50% of men choosing active surveillance will progress and require therapy. In this context, we will present recent data on the efficacy of 5-alpha-reductase inhibitors (5-ARIs) in secondary prevention among men with
David, Margel, Neil, Fleshner
openaire +2 more sources
Azasteroids as inhibitors of rat prostatic 5.alpha.-reductase
Journal of Medicinal Chemistry, 1984A series of A-ring heterocyclic steroids has been prepared and tested for inhibition of rat prostatic steroid 5 alpha-reductase in vitro. Strikingly high inhibitory activity was found with a group of 17 beta-substituted 4-methyl-4-aza-5 alpha-androstan-3-ones. These compounds were prepared from 3-keto-delta 4-precursors by oxidative (O3 or NaIO4-KMnO4)
G H, Rasmusson +6 more
openaire +2 more sources
[5-alpha-reductase inhibitors].
Acta urologica Belgica, 1995A reflection is made, on the one hand, on the lack of correlation between the intensity of micturition problems and the volume of the prostate and, on the other hand, on the different therapeutic approaches of irritative or obstructive voiding problems, and finally on the insufficiently convincing activity of Finasteride.
K, De Jaegher, P, Kozyreff, H, Claes
openaire +1 more source
Pharmacotherapy of benign prostatic hyperplasia: Inhibitor of 5 alpha-reductase
International Urology and Nephrology, 1997We studied the effects of 5 alpha-reductase inhibitor (finasteride) in the treatment of benign prostatic hyperplasia (BPH). This study is a randomized controlled trial. Sixty-two patients were treated with 5 alpha-reductase (finasteride 5 mg/day) and 61 patients (control group) with placebo for one year.
BAYRAKTAR, YILMAZ +4 more
openaire +3 more sources
Finasteride: the first 5 alpha-reductase inhibitor.
Pharmacotherapy, 1993Finasteride is a synthetic 4-azasteroid that is a specific competitive inhibitor of 5 alpha-reductase, an intracellular enzyme that converts testosterone to dihydrotestosterone (DHT). It has no binding affinity for androgen receptor sites and itself possesses no androgenic, antiandrogenic, or other steroid hormone-related properties.
S L, Sudduth, M J, Koronkowski
openaire +2 more sources
Finasteride: a 5 alpha-reductase inhibitor.
Clinical pharmacy, 1993The pharmacology and pharmacokinetics of finasteride are reviewed, and finasteride's clinical efficacy, adverse effects, and dosage in patients with benign prostatic hyperplasia (BPH) are described. Finasteride is a member of a new class of medications, the azasteroids, that have antiandrogenic activity limited to certain tissues, including the ...
openaire +1 more source
Prostate Cancer Prevention with 5 Alpha-Reductase Inhibitors
2010Testosterone gets converted into the more potent 5-[alpha]-dihydrotestosterone by 5-[alpha]- reductase. dihydrotestosterone (DHT) controls prostate mitotic activity and potentially prostate carcinogenesis. Interventions that inhibit 5-[alpha]-reductase have potential as preventive agents for prostate cancer.
openaire +2 more sources